TELO Stock Forecast 2025-2026
Distance to TELO Price Targets
TELO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Telomir (TELO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TELO and similar high-potential opportunities.
Latest TELO Stock Price Targets & Analyst Predictions
TELO has shown a year-to-date change of 11.2% and a 1-year change of -20.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for TELO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TELO Analyst Ratings
TELO Price Target Range
Latest TELO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TELO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Telomir Pharmaceuticals Inc. (TELO) Competitors
The following stocks are similar to Telomir based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Telomir Pharmaceuticals Inc. (TELO) Financial Data
Telomir Pharmaceuticals Inc. has a market capitalization of $149.71M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -810.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Telomir Pharmaceuticals Inc. (TELO) Business Model
About Telomir Pharmaceuticals Inc.
Develops innovative oncology and autoimmune therapies.
The company generates revenue by developing and commercializing advanced therapeutic solutions in oncology and autoimmune diseases. It focuses on a robust pipeline of drug candidates and collaborates with leading medical institutions to expedite the research and development process.
Telomir Pharmaceuticals operates within the dynamic healthcare sector, emphasizing precision medicine and targeted treatment approaches. Its involvement in clinical trials and collaborations positions it as a key player in the biotechnology and pharmaceutical industry, aiming to address unmet medical needs and improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Mr. Erez Aminov
Country
United States
IPO Year
N/A
Website
telomirpharma.comTelomir Pharmaceuticals Inc. (TELO) Latest News & Analysis
Telomir Pharmaceuticals (NASDAQ: TELO) reports new preclinical findings that Telomir-1 reverses calcium dysregulation and oxidative stress, protecting cell integrity and preventing cell death.
Positive findings on Telomir-1's effects on cellular health and aging could enhance Telomir Pharmaceuticals' market position and attract investment, potentially boosting stock prices.
Telomir Pharmaceuticals (NASDAQ:TELO) announced it has stabilized Silver(I) and Silver(II) in a biologically compatible form, enhancing potential applications in antimicrobial treatments and medical coatings.
Telomir's breakthrough in stabilizing silver ions could revolutionize medical applications, enhancing growth potential and market confidence, which may drive stock performance and investor interest.
Telomir Pharmaceuticals (NASDAQ:TELO) reported promising preclinical results showing that Telomir-1 can significantly reverse copper and iron-induced Reactive Oxygen Species elevation in human retinal cell lines.
Telomir Pharmaceuticals' breakthrough in reversing oxidative stress could lead to innovative treatments, boosting its market potential and attractiveness to investors focused on biotech advancements.
Oxidative stress is linked to aging and diseases including Alzheimer's, AMD, cardiovascular issues, cancer, diabetes, and worsens viral infections like avian influenza.
Research on oxidative stress highlights opportunities for investments in biotech and healthcare sectors focusing on aging-related therapies and treatments for chronic diseases and viral infections.
Telomir Pharmaceuticals (NASDAQ: TELO) announced significant findings from a preclinical study on progeria, conducted with Nagi Bioscience, focusing on age-reversal science.
Telomir Pharmaceuticals' breakthrough findings in age-reversal could enhance its market position and attract investment, impacting stock performance and future funding opportunities.
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
2 months agoTelomir Pharmaceuticals (NASDAQ: TELO) reported significant findings from copper binding studies with Telomir-1, targeting Wilson's disease and other copper-related disorders.
Telomir Pharmaceuticals' breakthrough in copper binding studies for Telomir-1 may enhance its market position in age-reversal and treatment of Wilson's disease, potentially boosting stock value.
Frequently Asked Questions About TELO Stock
What is Telomir Pharmaceuticals Inc.'s (TELO) stock forecast for 2025?
Based on our analysis of 0 Wall Street analysts, Telomir Pharmaceuticals Inc. (TELO) has a median price target of $15.25. The highest price target is $15.25 and the lowest is $15.25.
Is TELO stock a good investment in 2025?
Analyst ratings for TELO are not currently available. The stock is currently trading at $4.58. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TELO stock?
Wall Street analysts predict TELO stock could reach $15.25 in the next 12 months. This represents a 233.0% increase from the current price of $4.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Telomir Pharmaceuticals Inc.'s business model?
The company generates revenue by developing and commercializing advanced therapeutic solutions in oncology and autoimmune diseases. It focuses on a robust pipeline of drug candidates and collaborates with leading medical institutions to expedite the research and development process.
What is the highest forecasted price for TELO Telomir Pharmaceuticals Inc.?
The highest price target for TELO is $15.25 from at , which represents a 233.0% increase from the current price of $4.58.
What is the lowest forecasted price for TELO Telomir Pharmaceuticals Inc.?
The lowest price target for TELO is $15.25 from at , which represents a 233.0% increase from the current price of $4.58.
What is the overall TELO consensus from analysts for Telomir Pharmaceuticals Inc.?
Analyst ratings for TELO are not currently available. The stock is trading at $4.58.
How accurate are TELO stock price projections?
Stock price projections, including those for Telomir Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
